Malaria chemoprophylaxis with tafenoquine: A randomised study

Lancet

Volumn 355, Issue 9220, 2000, Pages 2041-2045

  Lell, Bertrand ^a,b   Faucher, Jean François ^a,b   Missinou, Michel Anoumou ^a,b   Borrmann, Steffen ^a,b   Dangelmaier, Oliver ^a,b   Horton, John ^c   Kremsner, Peter G ^a,b  

^a Albert Schweitzer Hospital   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAFENOQUINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; VERTIGO;

EID: 0034631384     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02352-7     Document Type: Article

References (20)

1. Garfield R. Malaria control in Nicaragua. social and political influences on disease transmission and control activities Lancet. 354:1999;414-418.
2. Brown V., Issak M.A., Rossi M., Barboza P., Paugam A. Epidemic of malaria in north-eastern Kenya. Lancet. 352:1998;1356-1357.
3. Greenwood A.M., Menendez C., Todd J., Greenwood B.M. The distribution of birth weights in Gambian women who received malaria chemoprophylaxis during their first pregnancy and in control women. Trans R Soc Trop Med Hyg. 88:1994;311-312.
4. Fleming A.F. The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Rev. 3:1989;18-28.
5. Menendez C., Kahigwa E., Hirt R.et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet. 350:1997;844-850.
6. Some E.S. Effects and control of highland malaria epidemic in Uasin Gishu District, Kenya. East Afr Med J. 71:1994;2-8.
7. Lobel H.O., Kozarsky P.E. Update on prevention of malaria for travelers. JAMA. 278:1997;1767-1771.
8. Lell B., Luckner D., Ndjavé M., Scott T., Kremsner P.G. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 351:1998;709-713.
9. Steffen R., Fuchs E., Schildknecht J.et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet. 341:1993;1299-1303.
10. Fryauff D.J., Baird J.K., Basri H.et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet. 346:1995;1190-1193.
11. Weiss W.R., Oloo A.J., Johnson A., Koech D., Hoffman S.L. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya. comparison with mefloquine, doxycycline, and chloroquine plus proguanil J Infect Dis. 171:1995;1569-1575.
12. Peters W., Robinson B.L., Milhous W.K. The chemotherapy of rodent malaria LI. Studies on a new 8-aminoquinoline, WR 238605. Ann Trop Med Hyg. 55:1993;243-249.
13. Brueckner R.P., Coster T., Wesche D.L., Shmuklarsky M., Schuster B.G. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Antimicrob Agents Chemother. 42:1998;1293-1294.
14. Walsh D.S., Looareesuwan S., Wilairatana P.et al. Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis. 180:1999;1282-1287.
15. Wildling E., Winkler S., Kremsner P.G., Brandts C., Jenne L., Wernsdorfer W.H. Malaria epidemiology in the province of Moyen Ogooué, Gabon. Trop Med Parasitol. 46:1995;77-82.
16. Lell B., May J., Schmidt-Ott R.J.et al. The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis. 28:1999;794-799.
17. Schlesselman J.J. Case-control studies. design, conduct, analysis New York: Oxford University Press. 1982;144-152.
18. Ederer F., Mantel N. Confidence limits on the ratio of two Poisson variables. Am J Epidemiol. 100:1974;165-167.
19. Brueckner R.P., Lasseter K.C., Lin E.T., Schuster B.G. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg. 58:1998;645-649.
20. Clyde D.F. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ. 59:1981;391-395.